filmov
tv
brentuximab vedotin
0:01:19
Dr. Smith Discusses Brentuximab Vedotin in CTCL
0:03:21
Brentuximab vedotin + nivolumab in lymphoma
0:05:16
Drug Development: Brentuximab Vedotin
0:03:07
Current indications for the use of brentuximab vedotin in Hodgkin lymphoma
0:02:43
Hodgkin Lymphoma: Using Brentuximab Vedotin Frontline
0:01:11
Brentuximab vedotin: current status and future considerations for this agent in HL treatment
0:01:08
Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma
0:05:14
Brentuximab Vedotin in Hodgkin Lymphoma
0:03:23
Brentuximab vedotin, nivolumab, doxorubicin & dacarbazine for early stage classical Hodgkin lymphoma
0:01:56
Toxicities associated with brentuximab vedotin in pediatric and adolescent Hodgkin lymphoma
0:01:53
The Rationale for Exploring Brentuximab Vedotin Plus AVD in Hodgkin Lymphoma
0:01:27
Treatment options for patients with Hodgkin lymphoma who progress after brentuximab vedotin
0:01:02
Seven-year OS analysis from ECHELON-1: brentuximab vedotin + AVD versus ABVD in Hodgkin lymphoma
0:02:27
Long-Term Efficacy and Safety of Brentuximab Vedotin in Hodgkin Lymphoma Patients
0:06:13
Brentuximab Vedotin
0:01:13
FDA Approval of Brentuximab Vedotin Plus AVD in Classical Hodgkin Lymphoma
0:01:30
Dr. William on Brentuximab Vedotin/Lenalidomide in Cutaneous/Peripheral T-Cell Lymphomas
0:00:56
PACIFIC: Brentuximab vedotin in mediastinal DLBCL
0:00:47
Dr. Rizvi on Brentuximab Vedotin Plus Checkpoint Inhibition in Hodgkin Lymphoma
0:06:57
Brentuximab Vedotin in CD30-Positive Lymphoma
0:02:46
ALCANZA: brentuximab vedotin for CTCL
0:05:54
Brentuximab Vedotin in Diffuse Large B-cell Lymphoma
0:00:47
Dr. Rizvi on Brentuximab Vedotin Combinations in Hodgkin Lymphoma
0:00:57
Advantages of Brentuximab Vedotin and Chemotherapy Combination for Advanced Stage Hodgkin Lymphoma
Вперёд
welcome to shbcf.ru